Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts

Impact · against what's priced in

Rhythm Pharmaceuticals shows strong early commercial momentum for IMCIVREE in the AHO indication, with broad prescriber adoption and an increased TAM estimate of up to 10,000 patients. Near-term catalysts include a potential Japan launch and German reimbursement, alongside the transition to an oral MC4R agonist in Phase III.

RYTM+0.60

No priced-in read yet